For Research Use Only. This product is supplied exclusively for laboratory research and is not intended for human or veterinary use.
Retatrutide (LY3437943) Research Peptide
Retatrutide, development code LY3437943, is a synthetic acylated peptide designed as an agonist at the GIP, GLP-1 and glucagon receptors. ZENTRA supplies it as lyophilised research material for controlled laboratory and analytical work.
Published literature includes receptor assays, animal research and developer-sponsored clinical trials. Those studies define the compound and its pharmacology; they do not make this research material an authorised medicine or establish a use outside properly regulated research.
Technical Specifications
| Product | Retatrutide |
|---|---|
| Research code | LY3437943 |
| Compound class | Synthetic acylated GIPR/GLP-1R/GCGR triple-receptor agonist peptide |
| Purity | Above 99% by third-party HPLC testing |
| Physical form | Lyophilised research material |
| Available formats | 10mg, 20mg, 30mg and 40mg |
| Intended use | Laboratory research and analytical use only |
Independent Batch Testing
Every current ZENTRA Retatrutide batch is independently tested and records an HPLC purity result above 99%. Use the batch number printed on the product label to locate the corresponding third-party report in our Batch Verification and COA Centre. Researchers should consult the individual report for the exact analytical methods, result and testing date for their supplied batch.
Retatrutide Research Context
The discovery paper characterised LY3437943 in cell-based receptor assays and preclinical models, reporting activity at all three target receptors with a GIPR-preferential profile. Subsequent trials investigated metabolic endpoints in defined clinical-research populations.
The compound remains investigational. ZENTRA does not provide treatment, dosing or administration guidance, and the published clinical results must not be used to infer the identity, sterility or suitability of an unlicensed research vial.
Storage and Handling
Keep unopened lyophilised material at approximately -20°C for long-term storage or at 2-8°C for short-term laboratory storage. Protect from light, moisture and repeated temperature changes. Follow the batch documentation and your institution’s validated preparation protocol.
Retatrutide Research FAQs
What is Retatrutide?
Retatrutide, or LY3437943, is an investigational synthetic peptide designed to activate GIP, GLP-1 and glucagon receptors.
Is Retatrutide a GLP-1-only compound?
No. Published receptor studies describe it as a triple agonist at GIPR, GLP-1R and GCGR.
How is batch purity checked?
Every current ZENTRA batch is independently analysed by HPLC and records a purity result above 99%. The corresponding report is available through online batch verification.
What physical form is supplied?
It is supplied as lyophilised research material in a sealed vial.
What evidence exists?
The literature includes cell, animal and developer-sponsored human clinical research. This page separates those published findings from any claim about use of the supplied research material.
Is this intended for human or veterinary use?
No. It is supplied strictly for laboratory research and analytical purposes and is not an authorised medicinal product.
Selected Scientific Sources
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease.
Research Resources
- MOTS-c Research Peptide
- Tesamorelin Research Peptide
- Batch Verification and COAs
- Research Compound Storage Guide
- Browse All Research Peptides
For research use only. Not for human or veterinary use.
